Siemens Gamesa Renewable Energy (OTCMKTS:GCTAY) & Zealand Pharma A/S (OTCMKTS:ZLDPF) Critical Review

Zealand Pharma A/S (OTCMKTS:ZLDPF) and Siemens Gamesa Renewable Energy (OTCMKTS:GCTAY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Volatility and Risk

Zealand Pharma A/S has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Siemens Gamesa Renewable Energy has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Zealand Pharma A/S and Siemens Gamesa Renewable Energy, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	0	1	2	3.67
Siemens Gamesa Renewable Energy	0	0	0	0	0.00

Profitability

This table compares Zealand Pharma A/S and Siemens Gamesa Renewable Energy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	-1,725.03%	-15.24%	-13.77%
Siemens Gamesa Renewable Energy	N/A	N/A	N/A

Valuation and Earnings

This table compares Zealand Pharma A/S and Siemens Gamesa Renewable Energy”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$9.09 million	495.06	-$102.18 million	($2.36)	-26.85
Siemens Gamesa Renewable Energy	$12.19 billion	1.05	-$749.21 million	N/A	N/A

Zealand Pharma A/S has higher earnings, but lower revenue than Siemens Gamesa Renewable Energy.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

About Siemens Gamesa Renewable Energy

Siemens Gamesa supplies wind turbines and power solutions to customers. The company is a global leader in the renewable energy industry specifically in the development, installation, maintenance, and manufacturing of wind turbines. Siemens Gamesa’s vision is to be the global leader in the renewable energy industry driving the transition towards a sustainable world. Siemens Gamesa was founded in 1976 and is based in Zamudio, Spain.